Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait.

Ahmed Swidan Gihan Hamdy Elsisi Mohamed M IbrahimMohammad AljazzarHossameldin Tawfik Sallam

Published in: Journal of medical economics (2023)

Adoption of dapagliflozin + ramipril is considered to be a cost saving option in addition to the improvement in QALYs in CKD patients with or without type-2 diabetes due to its nephroprotective effect, regardless of the aetiology of CKD, which eventually leads to reduction of dialysis and the transplantation cost burden on the Kuwaiti health care system. This study was focussed only on DAPA-CKD cohort.

Keyphrases

chronic kidney disease
end stage renal disease
type diabetes
cardiovascular disease
stem cells
insulin resistance
glycemic control
electronic health record
risk factors
metabolic syndrome
human health
cell therapy
skeletal muscle
climate change
bone marrow
peritoneal dialysis
mesenchymal stem cells